184 related articles for article (PubMed ID: 24870448)
1. Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts.
Chamorro S; Vela M; Franco-Villanueva A; Carramolino L; Gutiérrez J; Gómez L; Lozano M; Salvador B; García-Gallo M; Martínez-A C; Kremer L
MAbs; 2014; 6(4):1000-12. PubMed ID: 24870448
[TBL] [Abstract][Full Text] [Related]
2. 92R Monoclonal Antibody Inhibits Human CCR9
Somovilla-Crespo B; Martín Monzón MT; Vela M; Corraliza-Gorjón I; Santamaria S; Garcia-Sanz JA; Kremer L
Front Immunol; 2018; 9():77. PubMed ID: 29434597
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9
Santamaria S; Delgado M; Botas M; Castellano E; Corraliza-Gorjon I; Lafuente P; Muñoz-Calleja C; Toribio ML; Kremer L; Garcia-Sanz JA
Front Immunol; 2022; 13():825635. PubMed ID: 35967322
[TBL] [Abstract][Full Text] [Related]
4. Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry.
Nanamiya R; Takei J; Asano T; Tanaka T; Sano M; Nakamura T; Yanaka M; Hosono H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):101-106. PubMed ID: 34161159
[TBL] [Abstract][Full Text] [Related]
5. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
6. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Zhang S; Zheng C; Zhu W; Xiong P; Zhou D; Huang C; Zheng D
Theranostics; 2019; 9(18):5412-5423. PubMed ID: 31410224
[TBL] [Abstract][Full Text] [Related]
7. β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma.
Arruda DC; Santos LC; Melo FM; Pereira FV; Figueiredo CR; Matsuo AL; Mortara RA; Juliano MA; Rodrigues EG; Dobroff AS; Polonelli L; Travassos LR
J Biol Chem; 2012 Apr; 287(18):14912-22. PubMed ID: 22334655
[TBL] [Abstract][Full Text] [Related]
8. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
9. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
10. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
11. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
12. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
13. LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9/CCL25.
Li J; Muhammad J; Xie T; Sun J; Lei Y; Wei Z; Pan S; Qin H; Shao L; Jiang D; Zhang Q
Mol Immunol; 2021 Dec; 140():267-275. PubMed ID: 34808497
[TBL] [Abstract][Full Text] [Related]
14. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
[TBL] [Abstract][Full Text] [Related]
15. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
17. MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model.
Igaki K; Komoike Y; Nakamura Y; Watanabe T; Yamasaki M; Fleming P; Yang L; Soler D; Fedyk E; Tsuchimori N
Int Immunopharmacol; 2018 Jul; 60():160-169. PubMed ID: 29730559
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
Walters MJ; Wang Y; Lai N; Baumgart T; Zhao BN; Dairaghi DJ; Bekker P; Ertl LS; Penfold ME; Jaen JC; Keshav S; Wendt E; Pennell A; Ungashe S; Wei Z; Wright JJ; Schall TJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):61-9. PubMed ID: 20660125
[TBL] [Abstract][Full Text] [Related]
19. CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.
Lee S; Heinrich EL; Li L; Lu J; Choi AH; Levy RA; Wagner JE; Yip ML; Vaidehi N; Kim J
Mol Oncol; 2015 Oct; 9(8):1599-611. PubMed ID: 26003048
[TBL] [Abstract][Full Text] [Related]
20. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.
Ha KD; Bidlingmaier SM; Zhang Y; Su Y; Liu B
Mol Cell Proteomics; 2014 Dec; 13(12):3320-31. PubMed ID: 25149096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
